Key result
Finerenone plus empagliflozin shows promise for diabetic kidney disease in current clinical review.
Weekly journal scan highlights improved outcomes with finerenone/empagliflozin combination for diabetic kidney disease, suggesting potential treatment efficacy.
Journal Article Weekly Journal Scan: building CONFIDENCE in finerenone/empagliflozin combination for diabetic kidney disease Get access Daniela Pedicino , Daniela Pedicino Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli—IRCCS, Largo A. Gemelli 8, Rome 00168, Italy Corresponding author. Emails: [email protected], [email protected] https://orcid.org/0000-0002-4218-3066 Search for other works by this author on: Oxford Academic PubMed Google Scholar Massimo Volpe Massimo Volpe Department of Clinical and Molecular Medicine, Sapienza University of Rome, Via di Grottarossa 1035, Rome, ItalyIRCCS San Raffaele Roma, Via di Valcannuta 250, Rome, Italy https://orcid.org/0000-0002-9642-8380 Search for other works by this author on: Oxford Academic PubMed Google Scholar European Heart Journal, ehaf568, https://doi.org/10.1093/eurheartj/ehaf568 Published: 22 August 2025
No takes yet. Share an insight, caveat, or question.
Pedicino et al. (2025) conducted a review in diabetic kidney disease. finerenone/empagliflozin combination was evaluated. The finerenone and empagliflozin combination for diabetic kidney disease was discussed in a weekly journal scan, with no quantitative results reported in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: